Preventive Medicine
A Forum sector on early detection, screening and biomarker science, examining the investment case for predicting disease rather than treating it.
Preventive Medicine
Health systems built to treat disease are now being asked to predict it. Advances in imaging, molecular testing and biomarker science surface risk while patients are still well, moving clinical and financial value upstream. This sector examines how prediction is evidenced, reimbursed and financed.
The Cost of Waiting for Symptoms
Chronic conditions account for the majority of health expenditure in advanced economies. Most of that spending is committed after diagnosis. Prevention alters the arithmetic: disease delayed is cost avoided. Screening once confined to national programmes has become a commercial market, drawing private capital into tests, imaging and monitoring that were previously funded from public health budgets alone.
Key Thematic Areas
- Population screening and national prevention programmes
- Cancer screening pathways, recall and follow-up
- Biomarker validation and clinical utility evidence
- Advanced imaging and AI-assisted interpretation
- At-home sample collection and self-testing
- Occupational and executive health screening
Programme & Discussion Formats
- Deal Room – negotiation of distribution agreements, screening contracts and growth investment in diagnostic platforms.
- Evidence Sessions – clinical and health economic findings on what early detection delivers at scale.
- Policy Roundtables – closed discussions between health authorities, insurers and regulators on reimbursement for prevention.
- Technology Showcase – demonstrations of screening platforms, imaging systems and point-of-care devices.
- Signature Report – a dedicated chapter on the economics of prediction in the Forum's annual signature report, with its conclusions carried into the closing declaration.
Relevant Perspectives
- Public health agencies and national screening commissioners
- Insurers, reinsurers and employer benefit purchasers
- Diagnostics, imaging and medical device manufacturers
- Laboratory network operators and pathology service providers
- Health technology assessment and reimbursement bodies
- Specialist diagnostics investors and strategic acquirers
The Future of Preventive Medicine Investment
- Reimbursement Reform – payers moving from procedure-based coverage toward funding tests that prevent later admissions.
- Decentralised Testing – diagnostics moving out of central laboratories into pharmacies, workplaces and the home.
- AI-Assisted Triage – algorithms reading scans and pathology at volume where clinicians are scarce.
- Employer-Funded Prevention – large employers buying screening as a workforce productivity measure.
- Regulatory Clarity – approval pathways for predictive tests maturing, reducing risk for investors and adopters.
Key Benefits
- Commercial Counterparties – introductions to diagnostics ventures, laboratory operators and the buyers assessing them.
- Reimbursement Insight – evidence on which preventive models secure payer coverage and where that spending is growing.
- Policy Proximity – access to the officials and payers who decide whether a test reaches national scale.
- Partnership Formation – routes to validation sites, distribution partners and health system pilots.
- Evidence Presentation – a platform to put clinical results and health economic data before purchasers and investors.
Global Longevity Investors Forum (GLIF). A Global Investors Forum Platform.
This is an investment-sector topic. The GLIF programme is organised around five distinct strategic tracks. Session timings and programme participation will be announced.